Study of GS-4571 in Healthy Participants, Nondiabetic Obese Participants, and Nonobese Participants With Type 2 Diabetes Mellitus (T2DM)

Summary

The goal of this clinical study is to learn more about the study drug, GS-4571, and how safe it is in 3 groups, i) Healthy participants, ii) Healthy non-diabetic obese participants, and iii) Non-obese participants with Type 2 Diabetes Mellitus (T2DM). The primary objectives of this study are: To characterize the pharmacokinetics (PK) of GS-4571 following single and multiple ascending oral doses of GS-4571. To evaluate the effect of concomitant food intake and (if conducted) a representative acid-reducing agent (proton pump inhibitor (PPI), omeprazole) on the PK of GS-4571.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Weight Management

Eligibility basics and study details

Study type

Interventional

Phase

Phase 1

Ages

18 to 65 years

Sex

All

Healthy volunteers

Accepted

Sponsor

Gilead Sciences

Last updated on ClinicalTrials.gov

October 6, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites